CO4910138A1 - Tratamiento de las respuestas alergicas de las vias respira- torias superiores que utiliza dicha composicion para tratar sintomas de rini- tis alergica - Google Patents
Tratamiento de las respuestas alergicas de las vias respira- torias superiores que utiliza dicha composicion para tratar sintomas de rini- tis alergicaInfo
- Publication number
- CO4910138A1 CO4910138A1 CO97046887A CO97046887A CO4910138A1 CO 4910138 A1 CO4910138 A1 CO 4910138A1 CO 97046887 A CO97046887 A CO 97046887A CO 97046887 A CO97046887 A CO 97046887A CO 4910138 A1 CO4910138 A1 CO 4910138A1
- Authority
- CO
- Colombia
- Prior art keywords
- composition
- histamine
- receptor antagonist
- components
- decarboethoxylamine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Se obtiene alivio de los síntomas de rinitis mediante tratamientocon (a) una cantidad antihistamínica eficaz de un antagonista receptor de histamina H1 ; conjuntamente con (b) una cantidad suficiente de un antagonista receptor de histamina H3 para proveer un efecto descongestivo nasal. Los componentes pueden administrarse en una forma de dosificación conjunta única, o por separado en formas de dosificación iguales o diferentes para mantener los niveles sistémicos terapéuticos de ambos componentes. Una composición que comprende: (a) una cantidad antihistamínica eficaz de un antagonista receptor de histamina H1 ; y (b) una cantidad suficiente de un antagonista receptor de histamina H3 para proveer un efecto de descongestión nasal; en un portador farmacéuticamente aceptable. La composición de la reivindicación 1, en la que los componentes se combinan en una forma de dosificación sólida.La composición de la reivindicación 1, donde los componentes se combina en una forma de dosificación líquida. La composición de la reivindicación 1, donde el antagonista receptor de histamina H1 , está seleccionado del grupo que consiste en astemizol, azatadina, azelastina, acrivastina, bromfeniramina, clorfeniramina, clemastina, ciclizina, carebastina, ciproheptadina, carbinoxamina, descarboetoxiloratadina, doxilamina, difenhidramina, cetirizina, dimenhidrinato, dimetindeno, ebastina, epinastina, efletirizina, fexofenadina, hidroxizina, ketotifen, loratadina, levocabastina, mizolastina, mequitazina, mianserina, noberastina, meclizina, norastemizol, picumast, pirilamina, prometazina, terfenadina, tripelennamina, temelastina, trimeprazina y triprolidina y mezclas de los mismos. La composición de la reivindicación 1, en la que el antagonista receptor de histamina H3 está seleccionado del grupo que consiste en tioperamida, impromidina, burimamida, clobenpropit, impentamina, mifetidina, S-sopromidina, R-sopromidina, SKFI-91486 (3-imidazol-4-il)propilguanidina); GR-175737 (3-[(4-clorofenil)metil]-5-[2-(1H-imidazol-4-il)etil] 1,2,4-oxadiasola; GT-2016(4-(1-ciclohexilpentanoil- 4-piperidil)1H-imidazola; UCL-1199 (2- {[2-[4(5)-imidazolil]etil]tio}-5-nitropiridina, clozapina y mezclas de dos cualquiera o más de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68995196A | 1996-08-16 | 1996-08-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO4910138A1 true CO4910138A1 (es) | 2000-04-24 |
Family
ID=24770500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO97046887A CO4910138A1 (es) | 1996-08-16 | 1997-08-14 | Tratamiento de las respuestas alergicas de las vias respira- torias superiores que utiliza dicha composicion para tratar sintomas de rini- tis alergica |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP0920315B1 (es) |
| JP (2) | JP3638289B2 (es) |
| KR (1) | KR20000029975A (es) |
| CN (1) | CN1152682C (es) |
| AR (1) | AR008293A1 (es) |
| AT (1) | ATE314071T1 (es) |
| AU (1) | AU722040B2 (es) |
| BR (1) | BR9711149A (es) |
| CA (1) | CA2263163A1 (es) |
| CO (1) | CO4910138A1 (es) |
| CZ (1) | CZ43299A3 (es) |
| DE (1) | DE69734984D1 (es) |
| HU (1) | HUP9904362A3 (es) |
| ID (1) | ID17871A (es) |
| IL (1) | IL128573A0 (es) |
| MY (1) | MY116130A (es) |
| NO (1) | NO990706D0 (es) |
| NZ (1) | NZ334063A (es) |
| PE (1) | PE100298A1 (es) |
| PL (1) | PL191073B1 (es) |
| SK (1) | SK20099A3 (es) |
| TR (1) | TR199900326T2 (es) |
| TW (2) | TWI221768B (es) |
| WO (1) | WO1998006394A1 (es) |
| ZA (1) | ZA977263B (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ527201A (en) * | 1997-03-26 | 2004-12-24 | Sepracor Inc | Stable norastemizole formulations comprising coated norastemizole particles |
| NZ501248A (en) * | 1997-08-26 | 2001-06-29 | Aventis Pharma Inc | Pharmaceutical composition for combination of piperidinoalkanol-decongestant |
| US6034251A (en) * | 1997-11-07 | 2000-03-07 | Schering Corporation | Phenyl-alkyl-imidazoles |
| US5990147A (en) * | 1997-11-07 | 1999-11-23 | Schering Corporation | H3 receptor ligands of the phenyl-alkyl-imidazoles type |
| ES2188029T3 (es) * | 1997-11-07 | 2003-06-16 | Schering Corp | Fenil-alquil-imidazoles como antagonistas del receptor h3. |
| CN1130349C (zh) * | 1997-11-07 | 2003-12-10 | 先灵公司 | 苯基－烷基－咪唑类型的h3受体配体 |
| HUP0102662A3 (en) * | 1997-11-07 | 2003-01-28 | Schering Corp | Imidazoylalkyl substituted with a five, six or seven membered heterocyclic ring containing one nitrogen atom |
| US6384038B1 (en) * | 1998-04-14 | 2002-05-07 | Sepracor Inc. | Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants |
| EP1117405A2 (en) * | 1998-10-09 | 2001-07-25 | Schering Corporation | Composition and method for treating allergic diseases |
| US6100279A (en) * | 1998-11-05 | 2000-08-08 | Schering Corporation | Imidazoylalkyl substituted with a five, six or seven membered heterocyclic ring containing one nitrogen atom |
| EP1214071A2 (en) * | 1999-09-22 | 2002-06-19 | Schering Corporation | Treating allergic and inflammatory conditions using desloratadine |
| HUP0204048A3 (en) | 2000-02-03 | 2004-07-28 | Schering Corp | Use of desloratadine for treating allergic and inflammatory conditions |
| PE20020507A1 (es) | 2000-10-17 | 2002-06-25 | Schering Corp | Compuestos no-imidazoles como antagonistas del receptor histamina h3 |
| GB2373186A (en) * | 2001-02-23 | 2002-09-18 | Astrazeneca Ab | Pharmaceutical combinations of a CCR3 antagonist and a compound which is usefulreatment of asthma, allergic disease or inflammation |
| CN1298715C (zh) | 2001-03-13 | 2007-02-07 | 先灵公司 | 作为组胺h3拮抗剂的非咪唑化合物 |
| JP4563800B2 (ja) | 2002-04-18 | 2010-10-13 | シェーリング コーポレイション | ヒスタミンｈ３アンタゴニストとしての１−（４−ピペリジニル）ベンズイミダゾロン |
| US7105505B2 (en) | 2002-04-18 | 2006-09-12 | Schering Corporation | Benzimidazole derivatives useful as histamine H3 antagonists |
| DE60309598T2 (de) | 2002-06-24 | 2007-09-13 | Schering Corp. | Als histamin-h3-antagonisten geeignete indolderivate |
| US20050090527A1 (en) * | 2003-01-28 | 2005-04-28 | Schering Corporation | Combination of H1, H3 and H4 receptor antagonists for treatment of allergic and non-allergic pulmonary inflammation, congestion and allergic rhinitis |
| AU2006262441A1 (en) | 2005-06-20 | 2007-01-04 | Schering Corporation | Piperidine derivatives useful as histamine H3 antagonists |
| EP2318388A2 (en) | 2008-07-23 | 2011-05-11 | Schering Corporation | Tricyclic spirocycle derivatives and methods of use thereof |
| CA2739491A1 (en) | 2008-10-16 | 2010-04-22 | Schering Corporation | Azine derivatives and methods of use thereof |
| WO2010071822A1 (en) | 2008-12-19 | 2010-06-24 | Schering Corporation | Piperidine and piperazine derivatives and methods of use thereof |
| WO2010071819A1 (en) | 2008-12-19 | 2010-06-24 | Schering Corporation | Bicyclic heterocyclic derivatives and methods of use thereof |
| US9254286B2 (en) | 2009-03-17 | 2016-02-09 | Aciex Therapeutics, Inc. | Ophthalmic formulations of cetirizine and methods of use |
| US8569273B2 (en) | 2009-03-17 | 2013-10-29 | Aciex Therapeutics, Inc. | Ophthalmic formulations of cetirizine and methods of use |
| CN107582551A (zh) * | 2009-05-14 | 2018-01-16 | 总医院公司 | 治疗退化性及缺血性疾病的方法和组合物 |
| EP2485735B1 (en) | 2009-10-08 | 2015-07-29 | Merck Sharp & Dohme Corp. | Inhibitors of fatty acid binding protein (fabp) |
| WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
| RU2685277C1 (ru) * | 2018-05-24 | 2019-04-17 | Общество с ограниченной ответственностью "Фарминтерпрайсез Аллерджи" | Применение бисамидного производного малоновой кислоты для лечения аллергических и других заболеваний человека и животных |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU201683B (en) * | 1987-08-04 | 1990-12-28 | Biogal Gyogyszergyar | Process for producing pharmaceutical compositions for promoting healing of wounds |
| US5019591A (en) * | 1989-02-17 | 1991-05-28 | Pennsylvania Research Corporation | Method for treating retinopathy and other small vessel disorders associated with diabetes |
| GB9303210D0 (en) * | 1993-02-17 | 1993-03-31 | Univ Manitoba | Cancer treatment |
-
1997
- 1997-08-13 IL IL12857397A patent/IL128573A0/xx unknown
- 1997-08-13 ZA ZA9707263A patent/ZA977263B/xx unknown
- 1997-08-13 MY MYPI97003708A patent/MY116130A/en unknown
- 1997-08-13 AT AT97937153T patent/ATE314071T1/de not_active IP Right Cessation
- 1997-08-13 WO PCT/US1997/013903 patent/WO1998006394A1/en not_active Application Discontinuation
- 1997-08-13 BR BR9711149A patent/BR9711149A/pt not_active Application Discontinuation
- 1997-08-13 CZ CZ99432A patent/CZ43299A3/cs unknown
- 1997-08-13 KR KR1019997001226A patent/KR20000029975A/ko active IP Right Grant
- 1997-08-13 TR TR1999/00326T patent/TR199900326T2/xx unknown
- 1997-08-13 AU AU39733/97A patent/AU722040B2/en not_active Ceased
- 1997-08-13 CN CNB971987130A patent/CN1152682C/zh not_active Expired - Fee Related
- 1997-08-13 DE DE69734984T patent/DE69734984D1/de not_active Expired - Lifetime
- 1997-08-13 CA CA002263163A patent/CA2263163A1/en not_active Abandoned
- 1997-08-13 HU HU9904362A patent/HUP9904362A3/hu unknown
- 1997-08-13 SK SK200-99A patent/SK20099A3/sk unknown
- 1997-08-13 TW TW086111627A patent/TWI221768B/zh not_active IP Right Cessation
- 1997-08-13 TW TW093112764A patent/TW200427450A/zh unknown
- 1997-08-13 AR ARP970103693A patent/AR008293A1/es unknown
- 1997-08-13 PE PE1997000705A patent/PE100298A1/es not_active Application Discontinuation
- 1997-08-13 JP JP50985998A patent/JP3638289B2/ja not_active Expired - Fee Related
- 1997-08-13 EP EP97937153A patent/EP0920315B1/en not_active Expired - Lifetime
- 1997-08-13 PL PL331617A patent/PL191073B1/pl not_active IP Right Cessation
- 1997-08-13 NZ NZ334063A patent/NZ334063A/xx unknown
- 1997-08-14 ID IDP972837A patent/ID17871A/id unknown
- 1997-08-14 CO CO97046887A patent/CO4910138A1/es unknown
-
1999
- 1999-02-15 NO NO990706A patent/NO990706D0/no unknown
-
2002
- 2002-07-30 JP JP2002222138A patent/JP2003095979A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| NZ334063A (en) | 2000-09-29 |
| AU722040B2 (en) | 2000-07-20 |
| NO990706L (no) | 1999-02-15 |
| WO1998006394A1 (en) | 1998-02-19 |
| SK20099A3 (en) | 2000-08-14 |
| ATE314071T1 (de) | 2006-01-15 |
| HUP9904362A2 (hu) | 2000-11-28 |
| EP0920315A1 (en) | 1999-06-09 |
| DE69734984D1 (de) | 2006-02-02 |
| BR9711149A (pt) | 1999-08-17 |
| NO990706D0 (no) | 1999-02-15 |
| KR20000029975A (ko) | 2000-05-25 |
| TR199900326T2 (xx) | 1999-05-21 |
| JP3638289B2 (ja) | 2005-04-13 |
| CA2263163A1 (en) | 1998-02-19 |
| ZA977263B (en) | 1998-02-16 |
| AR008293A1 (es) | 1999-12-29 |
| IL128573A0 (en) | 2000-01-31 |
| JP2003095979A (ja) | 2003-04-03 |
| PL331617A1 (en) | 1999-08-02 |
| TW200427450A (en) | 2004-12-16 |
| HUP9904362A3 (en) | 2000-12-28 |
| JP2000505094A (ja) | 2000-04-25 |
| CZ43299A3 (cs) | 1999-07-14 |
| CN1233179A (zh) | 1999-10-27 |
| TWI221768B (en) | 2004-10-11 |
| EP0920315B1 (en) | 2005-12-28 |
| CN1152682C (zh) | 2004-06-09 |
| PE100298A1 (es) | 1999-01-11 |
| PL191073B1 (pl) | 2006-03-31 |
| MY116130A (en) | 2003-11-28 |
| ID17871A (id) | 1998-02-05 |
| AU3973397A (en) | 1998-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO4910138A1 (es) | Tratamiento de las respuestas alergicas de las vias respira- torias superiores que utiliza dicha composicion para tratar sintomas de rini- tis alergica | |
| Diaz et al. | The control of sarcoplasmic reticulum Ca content in cardiac muscle | |
| PE20040608A1 (es) | Compuestos de alquino con efecto antagonico de la hcm y medicamentos que los contienen | |
| PE20060259A1 (es) | Compuestos de quinuclidina como antagonistas del receptor de acetilcolina muscarinico | |
| RU2190425C2 (ru) | Способ и композиция для лечения и предупреждения гиперурикемии | |
| ES2069223T3 (es) | Toallas de papel que tienen capa voluminosa. | |
| BRPI0516541A (pt) | composição para cuidado pessoal contendo uma fase de limpeza e uma fase de benefìcio | |
| JP2005330266A5 (es) | ||
| BR0315831A (pt) | Composição lìquida listrada para higiene pessoal contendo uma fase de limpeza e uma fase de benefìcio separada com melhor estabilidade | |
| ES2230378T3 (es) | Combinacion de agonistas de gaba e inhibidores de sorbitol deshidrogenasa. | |
| CO4440476A1 (es) | Composicion sinergistica que comprende una combinacion plaguicida de ingredientes activos . | |
| WO2013009830A1 (en) | Methods of treatment | |
| ECSP045240A (es) | Stents recubiertos con n-{5-[4-(4-metil-piperazino-metil)-benozilamido]-2-metilfenil}-4-(3-piridil)-2-pirimidin-amina | |
| PE20090806A1 (es) | Derivados de triazol que son antagonistas de smo | |
| BR9917112A (pt) | Compostos de imidazol e seu uso medicinal | |
| RU2002119016A (ru) | N-[5-[[[5-алкил-2-оксазолил]метил]тио]-2-тиазолил]карбоксамидные ингибиторы циклин-зависимых киназ | |
| JP2005511724A5 (es) | ||
| ECSP066587A (es) | Forma no efervescente del naproxeno sódico que comprende bicarbonato sódico | |
| BRPI0717868A2 (pt) | Composição farmacêutica possuindo atividade antipsicótica, antidepressiva ou antiepiléptica com efeito colateral reduzido | |
| KR910000684A (ko) | 소염제 페나메이트 1,3,4-티아디아졸 및 1,3,4-옥사디아졸 | |
| RU98107337A (ru) | Производные изоксазола | |
| ATE464047T1 (de) | Topische anwendung von thiazolylamiden | |
| PE108199A1 (es) | Composicion farmaceutica de tiazolidindiona y sulfonilurea | |
| ITMI20021098A1 (it) | Struttura integrata atta a realizzare all'interno di una sacca dielettricamente isolata un componente mos | |
| Sıdır et al. | Structure–activity relationships for novel drug precursor N-substituted-6-acylbenzothiazolon derivatives: A theoretical approach |